The DPCD Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HeLa human cervical adenocarcinoma cell line, designed to disrupt the expression of the DPCD gene. This polyclonal knockout pool provides a versatile loss-of-function model for investigating the role of DPCD in ciliary biology without requiring single-cell clone isolation. The heterogeneous nature of the population allows researchers to assess phenotypic variability and select for further studies.
HeLa cells are an immortalized epithelial cell line originating from a cervical adenocarcinoma, widely utilized in cancer research and cell biology. These cells contain integrated human papillomavirus 18 (HPV18) DNA, leading to the inactivation of the tumor suppressors p53 and Rb by viral oncoproteins. Although HeLa cells are typically non-ciliated under standard culture conditions, they can be induced to form primary cilia upon serum starvation or specific signaling cues, making them a tractable system for studying ciliary assembly and function in a transformed cellular context.
The DPCD gene encodes a critical component of the outer dynein arm (ODA) docking complex within motile cilia. DPCD protein functions in the attachment of ODAs to the doublet microtubules of the axoneme, a process essential for generating coordinated ciliary beating. Mechanistically, DPCD operates downstream of transcriptional regulators such as FOXJ1, RFX transcription factors, and multicilin, which drive ciliogenesis. DPCD interacts with other docking complex members including CCDC103, CCDC114, and ARMC4, and is required for proper localization of ODA motor proteins such as DNAH5 and DNAI1. Disruption of DPCD impairs ODA assembly, resulting in reduced ciliary beat frequency and defective mucociliary clearance, thereby linking it to pathways like Hedgehog signaling that depend on functional cilia.
In the HeLa background, knockout of DPCD creates a valuable model to dissect the molecular requirements for ODA docking independent of organismal complexity. Given HeLa cells?? capacity for ciliogenesis induction, this polyclonal knockout population enables the study of ciliary motility defects in a cancer-derived cell line. It is particularly relevant for primary ciliary dyskinesia (PCD) research, including Kartagener syndrome, and for investigating ciliopathy-associated chronic respiratory infections and infertility. The model can be used to delineate how loss of DPCD affects downstream ODA components and ciliary signaling, providing insights into disease mechanisms.
This knockout model supports a range of experimental approaches: verification of DPCD disruption by western blotting and RT-qPCR; immunofluorescence staining to examine mislocalization of ODA proteins like DNAH5; high-speed video microscopy to quantify ciliary beat frequency defects; air-liquid interface cultures combined with mucociliary transport assays to assess functional consequences; transmission electron microscopy (TEM) for ultrastructural axonemal analysis; and flow cytometry to evaluate cell cycle effects in the absence of DPCD. These applications make the DPCD Knockout HeLa Polyclonal Cells a robust platform for advancing ciliopathy research and drug discovery. For further details or to discuss your experimental needs, contact Ascent Research.
